{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:10:00Z","timestamp":1788851400143,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560144"],"award-info":[{"award-number":["82560144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"High-Level Medical and Health Talent Project of \u201cTianshan Talents\u201d Cultivation Plan","award":["TSYC202401A019"],"award-info":[{"award-number":["TSYC202401A019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03784-0","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:50:56Z","timestamp":1788850256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5133-9147","authenticated-orcid":false,"given":"Chahan","family":"Suolinge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1331-4713","authenticated-orcid":false,"given":"Cai","family":"Dema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3344-1325","authenticated-orcid":false,"given":"Xinyue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8429-9784","authenticated-orcid":false,"given":"Bijian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-4087","authenticated-orcid":false,"given":"Chen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3259-4441","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"1","key":"3784_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou E, Seikrit C, Tang SCW, Boor P, Tesa\u0159 V, Floege J, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9(1):67.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"3784_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"3784_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/jama.2025.25020","volume":"335","author":"S Stoneman","year":"2026","unstructured":"Stoneman S, Teh JW, O\u2019Shaughnessy MM. IgA Nephropathy in Adults: A Review. JAMA. 2026;335(9):799\u2013813.","journal-title":"JAMA"},{"issue":"12","key":"3784_CR4","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177\u201383.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3784_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70393","volume":"14","author":"D Xu","year":"2026","unstructured":"Xu D, Zhang M, Liang W, Fang L, Ge F. Risk factors of disease progression in IgA nephropathy: a systematic review and meta-analysis. Immun Inflamm Dis. 2026;14(2):e70393.","journal-title":"Immun Inflamm Dis"},{"key":"3784_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.539545","volume":"11","author":"S Han","year":"2020","unstructured":"Han S, Yao T, Lu Y, Chen M, Xu Y, Wang Y. Efficacy and safety of immunosuppressive monotherapy agents for IgA nephropathy: a network meta-analysis. Front Pharmacol. 2020;11:539545.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3784_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","volume":"35","author":"K El Karoui","year":"2024","unstructured":"El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol. 2024;35(1):103\u201316.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3784_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ekir.2017.02.003","volume":"2","author":"Q Cai","year":"2017","unstructured":"Cai Q, Xie X, Wang J, Shi S, Liu L, Chen Y, et al. Severe adverse effects associated with corticosteroid treatment in patients with IgA nephropathy. Kidney Int Rep. 2017;2(4):603\u20139.","journal-title":"Kidney Int Rep"},{"key":"3784_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123027","author":"T Kano","year":"2022","unstructured":"Kano T, Suzuki H, Makita Y, Nihei Y, Fukao Y, Nakayama M, et al. Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10123027.","journal-title":"Biomedicines"},{"issue":"9","key":"3784_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.34067\/KID.0002382022","volume":"3","author":"L Sanchez-Russo","year":"2022","unstructured":"Sanchez-Russo L, Rajasekaran A, Bin S, Faith J, Cravedi P. The gut and kidney crosstalk in immunoglobulin A nephropathy. Kidney360. 2022;3(9):1630\u20139.","journal-title":"Kidney360"},{"issue":"8","key":"3784_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2174\/1566524023666230720112215","volume":"24","author":"Y Huang","year":"2024","unstructured":"Huang Y, Sun X, Nie G, Xu H, Zou M. Follicular helper T cells in Peyer\u2019s patches and galactose- deficient IgA1 contribute to IgA nephropathy. Curr Mol Med. 2024;24(8):1033\u201344.","journal-title":"Curr Mol Med"},{"issue":"10","key":"3784_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1681\/ASN.2018111156","volume":"30","author":"DV Rizk","year":"2019","unstructured":"Rizk DV, Saha MK, Hall S, Novak L, Brown R, Huang ZQ, et al. Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1. J Am Soc Nephrol. 2019;30(10):2017\u201326.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3784_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3949\/ccjm.92a.24105","volume":"92","author":"S Ramsawak","year":"2025","unstructured":"Ramsawak S, Cohen S, Linares A, Cavanaugh C. IgA nephropathy: update on pathogenesis and treatment. Cleve Clin J Med. 2025;92(6):373\u201383.","journal-title":"Cleve Clin J Med"},{"key":"3784_CR14","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.2147\/DDDT.S383138","volume":"18","author":"J Barratt","year":"2024","unstructured":"Barratt J, Kristensen J, Pedersen C, Jerling M. Insights on Nefecon(\u00ae), a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy. Drug Des Devel Ther. 2024;18:3415\u201328.","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"3784_CR15","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","volume":"26","author":"HK Smerud","year":"2011","unstructured":"Smerud HK, B\u00e1r\u00e1ny P, Lindstr\u00f6m K, Fernstr\u00f6m A, Sandell A, P\u00e5hlsson P, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant. 2011;26(10):3237\u201342.","journal-title":"Nephrol Dial Transplant"},{"issue":"10084","key":"3784_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327.","journal-title":"Lancet"},{"issue":"10405","key":"3784_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370.","journal-title":"Lancet"},{"key":"3784_CR18","unstructured":"Laws L. FDA grants priority review for full approval of Calliditas' Tarpeyo to slow kidney decline. Global Pharma. 2023 2023\/08\/18\/."},{"key":"3784_CR19","unstructured":"Everest Medicines Announces NMPA Full Approval of NEFECON\u00ae for the Treatment of Primary Immunoglobulin A Nephropathy (IgAN) in Adults at Risk of Disease Progression 2025. Available from: https:\/\/www.prnewswire.com\/apac\/news-releases\/everest-medicines-announces-nmpa-full-approval-of-nefecon-for-the-treatment-of-primary-immunoglobulin-a-nephropathy-igan-in-adults-at-risk-of-disease-progression-302447423.html."},{"issue":"4s","key":"3784_CR20","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","volume":"108","author":"BH Rovin","year":"2025","unstructured":"Rovin BH, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, et al. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108(4s):S1-s71.","journal-title":"Kidney Int"},{"issue":"2","key":"3784_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","volume":"84","author":"C Tang","year":"2024","unstructured":"Tang C, Chen P, Si FL, Lv JC, Shi SF, Zhou XJ, et al. Time-varying proteinuria and progression of IgA nephropathy: a cohort study. Am J Kidney Dis. 2024;84(2):170-8.e1.","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"3784_CR22","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"key":"3784_CR23","doi-asserted-by":"crossref","unstructured":"KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s):S1-s276.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"4","key":"3784_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0046-8177(82)80221-9","volume":"13","author":"SM Lee","year":"1982","unstructured":"Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13(4):314\u201322.","journal-title":"Hum Pathol"},{"issue":"5","key":"3784_CR25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2016","unstructured":"Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2016;91(5):1014\u201321.","journal-title":"Kidney Int"},{"issue":"12","key":"3784_CR26","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.34067\/KID.0000000583","volume":"5","author":"H Zhang","year":"2024","unstructured":"Zhang H, Lafayette R, Wang B, Ying L, Zhu Z, Stone A, et al. Efficacy and safety of Nefecon in patients with IgA nephropathy from mainland China: 2-year NefIgArd trial results. Kidney360. 2024;5(12):1881\u201392.","journal-title":"Kidney360"},{"issue":"2","key":"3784_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1681\/ASN.2021070948","volume":"33","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Tighiouart H, Heerspink HJL, Vonesh EF, Chaudhari J, Miao S, et al. Acute treatment effects on GFR in randomized clinical trials of kidney disease progression. J Am Soc Nephrol. 2022;33(2):291\u2013303.","journal-title":"J Am Soc Nephrol"},{"key":"3784_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04991-4","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Lin Y, Wang W, Li G, Chen S. Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis. Int Urol Nephrol. 2026. https:\/\/doi.org\/10.1007\/s11255-025-04991-4.","journal-title":"Int Urol Nephrol"},{"key":"3784_CR29","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3389\/fimmu.2026.1831633","volume":"17","author":"T Cui","year":"2026","unstructured":"Cui T, Wu H, Zhu W, Lin J, Li S, Sui Y, et al. Targeted-release budesonide versus systemic corticosteroids in IgA nephropathy: a real-world comparative study. Front Immunol. 2026;17:2026.","journal-title":"Front Immunol"},{"key":"3784_CR30","doi-asserted-by":"publisher","first-page":"1722582","DOI":"10.3389\/fneph.2025.1722582","volume":"5","author":"A Shah","year":"2025","unstructured":"Shah A, Maski M, Egbuna O, Longstaff W, Stricker-Shaver J, Barber B. Lower proteinuria is better for patients with IgA nephropathy: a systematic review. Front Nephrol. 2025;5:1722582.","journal-title":"Front Nephrol"},{"issue":"11","key":"3784_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.101104","volume":"7","author":"X Shen","year":"2025","unstructured":"Shen X, Chen P, Hui M, Li J, Hou W, Yang H, et al. Association between relapse and long-term kidney outcomes in IgA nephropathy. Kidney Med. 2025;7(11):101104.","journal-title":"Kidney Med"},{"issue":"3","key":"3784_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Ai L, Floege J, Perkovic V, Boyer-Suavet S, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"3784_CR33","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang Z, Liu X, Shi S, Lv J, Zhang Y, et al. Exploring novel adverse events of Nefecon. Kidney Int Rep. 2024;9(9):2705\u201317.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3784_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1365-2036.2003.01386.x","volume":"17","author":"PD Lundin","year":"2003","unstructured":"Lundin PD, Edsb\u00e4cker S, Bergstrand M, Ejderhamn J, Linander H, H\u00f6gberg L, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn\u2019s disease. Aliment Pharmacol Ther. 2003;17(1):85\u201392.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3784_CR35","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432\u201342.","journal-title":"JAMA"},{"issue":"23","key":"3784_CR36","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225\u201336.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03784-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:50:58Z","timestamp":1788850258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":36,"alternative-id":["3784"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03784-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"25 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Chahan Suolinge, Cai Dema, Xinyue Wu, Bijian Jiang, Chen Lu and Jing Li declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (Ethical Approval Number: NO. 260414-17). All patients provided written informed consent. This study was conducted in accordance with the Declaration of Helsinki, the international standards of good clinical practice, and applicable local laws and regulations.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}